| General Information of Drug (ID:
DR2826) |
| Drug Name |
Nivolumab
|
| Synonyms |
Nivolumab; Nivolumab [USAN:INN]; Opdivo; UNII-31YO63LBSN; 31YO63LBSN |
| Indication |
Lung cancer
[ICD11: 2C25]
|
Approved
|
[1]
|
|
|
|
|
|
|
|
| The Metabolic Roadmap of This Drug |
|
|
| The Full List of Drug Metabolites (DM) of This Drug |
| DM Name |
DM ID |
PubChem ID |
Reaction |
DM Level |
REF |
|
Amino acid
|
DM002455
|
N. A. |
Unclear |
1 |
[3]
|
|
Peptide
|
DM002454
|
N. A. |
Unclear |
1 |
[3]
|
|
|
|
|
|
|
|
| The Full List of Metabolic Reaction (MR) of This Drug |
|
|
|
|
|
|
|
|
| Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug |
| DME Name |
DME Info |
Species |
Uniprot ID |
EC Number |
REF |
|
Unclear metabolic mechanism (DME-unclear)
|
DME1449
|
Prevotella copri
|
Not Available |
Not Available |
[2]
|
|
|
|
|
|
|
|
| References |
| 1 |
Nivolumab was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
|
| 2 |
The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC. J Thorac Oncol. 2019 Aug;14(8):1378-1389.
|
| 3 |
DrugBank(Pharmacology-Metabolism)Nivolumab
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
